2023 China Focus @Boston Summit
On June 4, 2023 (Eastern Time), The 2023 China Focus @Boston conference, jointly organized by MybioGate, CUBIO (Bio-Innovation Center), ENMORE Healthcare and SAPA, will open in Boston, USA. The conference will be the first overseas offline meeting of CHINA FOCUS after the global COVID-19 pandemic, and the third time for MybioGate to hold China Focus at BIO International.
Looking back on the past three years, the global biopharmaceutical market has experienced the baptism of the cold winter and is slowly recovering. After the epidemic outbreak around the world, the exchanges between Chinese and foreign biomedical industries have become more frequent and closer.
In the past 2022, according to incomplete statistics, there were a total of 130 license-in/out transactions between biopharmaceuticals in China and around the world, including 80 license-in transactions and 51 license-out transactions. Innovative pharmaceutical companies in China are accelerating their research and development, and China’s License-out has become an important means for enterprises to move towards globalization. Chinese pharmaceutical companies must always maintain a keen sense of global biopharmaceutical market trends and seize opportunities while dedicating themselves to accelerating clinical product development.
At 2023 China Focus @Boston, we will invite the MNC Global BD Head, Chairman/CEO of Chinese listed companies, CEOs and BD executives of Chinese and foreign Biotech companies, partners of investment institutions and other industry insiders to discuss topics such as the internationalization strategy of Chinese enterprises, MNC’s strategic layout in the world, China Biotech’s investment and financing strategies, and global investment and opportunities in synthetic biology.
The conference will be focused on two main topics: biopharmaceutical investment BD cooperation and process technology exploration, and a special roadshow for Chinese biopharmaceutical enterprises.
Registration: Scan the QR code to register. Once approved, an email notification will be sent.
Contact: Youwen Dai